周剂量多西他赛联合顺铂二线治疗晚期非小细胞肺癌临床观察

目的观察多西他赛周剂量给药联合顺铂方案二线治疗晚期非小细胞肺癌（NSCLC）的临床疗效及毒副作用。方法2003年1月－2007年3月收治的54例既往治疗失败的ⅢB-Ⅳ期NSCLC患者，多西他赛35mg／m^2静脉点滴1小时，第1、8天，DDP25mg／m^2静脉点滴，第1～3天，21天为1个周期。结果54例中CR3例，PR9例，NC29例，PD13例。总有效率（RR）为22．3％（12／54），临床获益率为76％。全组中位TTP为4个月（2—9个月），中位生存期10月，1年生存率为39％，主要毒副作用为骨髓抑制，白细胞下降占64．8％（35／54），达到Ⅲ～Ⅳ度的为9．3％（5／54）；非血液学毒副作用性轻微；全组无治疗相关性死亡。结论周剂量多西他赛联合顺铂方案二线治疗晚期非小细胞肺癌疗效较好，耐受性佳。

The clinical study of weekly docetaxel and cisplatin as a second-line therapy for recurrent or progressive non-small cell lung cancer

Objective To observe the efficacy and toxicity of weekly docetaxel and cisplatin in the treatment of patients with recurrent or progressive non-smaU cell lung cancer （NSCLC）. Methods Totally 54 patients with advanced NSCLC treated were enrolled into the study. Docetaxel was administered at a dose of 35rag/ m^2 on dl and d8 and cisplatin at a dose 25mg/m^2 from dl to d3. The chemotherapy was repeated every 21 days. Results Three patients achieved CR, 9 PR, 29 NC, and 13 PD. The overall response rate was 22. 3%. The major toxic reactions were tolerable myelo - suppression （9. 3% in grade Ⅲ ＋ Ⅳ）. The none- hematological toxicity was mild. Conclusions The therapy of weekly docetaxel plus cisplatin is effective and well-tolerated as a second-line treatment of recurrent or progressive NSCLC patients.